Utilization and dosing of angiotensin-converting enzyme inhibitors for heart failure: Effect of physician specialty and patient characteristics

Journal of General Internal Medicine

Volumn 12, Issue 9, 1997, Pages 563-566

  Chin, Marshall H ^a   Wang, John C ^b,c   Zhang, James X ^a   Lang, Roberto M ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Angiotensin converting enzyme (ACE) inhibitor; Congestive heart failure; Physician behavior; Quality of care; Specialty

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; AGED; ARTICLE; DOSE RESPONSE; ENZYME INHIBITION; FEMALE; HEALTH CARE QUALITY; HEART EJECTION FRACTION; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; PATIENT ATTITUDE; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; SYSTOLIC BLOOD PRESSURE;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOLOGY; CHICAGO; CROSS-SECTIONAL STUDIES; DRUG UTILIZATION REVIEW; FEMALE; HEART FAILURE, CONGESTIVE; HOSPITALS, UNIVERSITY; HUMANS; INTERNAL MEDICINE; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; RETROSPECTIVE STUDIES;

EID: 0030875875     PISSN: 08848734     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1497.1997.07110.x     Document Type: Article

References (20)

1. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302.
2. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327:685-91.
3. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardiol infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992;327:669-77.
4. Chin MH, Goldman L. Factors contributing to the hospitalization of patients with congestive heart failure. Am J Public Health. 1997; 87:643-8.
5. McDermott MM, Feinglass J, Sy J, Gheorghiade M. Hospitalized congestive heart failure patients with preserved versus abnormal left ventricular systolic function: clinical characteristics and drug therapy. Am J Med. 1995;99:629-35.
6. Philbin EF, Andreaou C, Rocco TA, Lynch LJ, Baker SL. Patterns of angiotensin-converting enzyme inhibitor use in congestive heart failure in two community hospitals. Am J Cardiol. 1996;77:832-8.
7. Havranek EP, Graham GW, Pan Z, Lowes B. Process and outcome of outpatient management of heart failure: a comparison of cardiologists and primary care providers. Am J Manag Care. 1996;2:783-9.
8. Young JB, Weiner DH, Yusuf S, et al. Patterns of medication use in patients with heart failure: a report from the Registry of Studies of Left Ventricular Dysfunction (SOLVD). South Med J. 1995;88: 514-23.
9. Chin MH, Friedmann PD, Cassel CK, Lang RM. Differences in generalist and specialist physicians' knowledge and use of angiotensin-converting enzyme inhibitors for congestive heart failure. J Gen Intern Med. 1997;12:523-30.
10. Rajfer SI. Perspective of the pharmaceutical industry on the development of new drugs for heart failure. J Am Coll Cardiol. 1993; 22(suppl A):198-200A.
11. Chodoff P, Bischof RO, Nash DB, Laine C. The AHCPR guidelines on heart failure: comparison of a family medicine and an internal medicine practice with the guidelines and an educational intervention to modify behavior. Clin Performance Qual Healthcare. 1996; 4:179-85.
12. Konstam M, Dracup K, Baker D, et al. Heart Failure: Evaluation and Care of Patients with Left-Ventricular Systolic Dysfunction. Clinical Practice Guideline No. II. Rockville, Md: Agency for Health Care Policy and Research, Public Health Service, U.S. Department of Health and Human Services; June 1994. AHCPR publication no. 94-0612.
13. American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Guidelines for the evaluation and management of heart failure. J Am Coll Cardiol. 1995;26:1376-98.
14. U.S. Health Care Financing Administration. The International Classification of Diseases, 9th Revision, Clinical Modification. Washington, DC: U.S. Department of Health and Human Services; 1991.
15. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis. 1987;40:373-83.
16. Cleland JGF, Hubbard WN, Pittard J, Poole-Wilson PA, Sutton GC. ACE inhibitors in heart failure: what dose? BMJ. 1995;71:65-6.
17. O'Connell JB, Cobb AB. Heart failure evaluation and treatment in Mississippi: results from a survey of the Mississippi foundation for medical care. J Miss State Med Assoc. 1996;37:648-51.
18. Lamas GA, Pfeffer MA, Hamm P, Wertheimer J, Rouleau JL, Braunwald E. Do the results of randomized clinical trials of cardiovascular drugs influence medical practice? N Engl J Med. 1992;327:241-7.
19. Packer M. Do angiotensin-converting enzyme inhibitors prolong life in patients with heart failure treated in clinical practice? J Am Coll Cardiol. 1996;28:1323-7.
20. Visser FC, Visser CA. Current controversies with ACE inhibitor treatment in heart failure. Cardiology. 1996;87(suppl 1):23-8.